Peter Ackerman

1.3k total citations
30 papers, 523 citations indexed

About

Peter Ackerman is a scholar working on Infectious Diseases, Virology and Hepatology. According to data from OpenAlex, Peter Ackerman has authored 30 papers receiving a total of 523 indexed citations (citations by other indexed papers that have themselves been cited), including 24 papers in Infectious Diseases, 16 papers in Virology and 9 papers in Hepatology. Recurrent topics in Peter Ackerman's work include HIV/AIDS drug development and treatment (22 papers), HIV Research and Treatment (16 papers) and HIV/AIDS Research and Interventions (13 papers). Peter Ackerman is often cited by papers focused on HIV/AIDS drug development and treatment (22 papers), HIV Research and Treatment (16 papers) and HIV/AIDS Research and Interventions (13 papers). Peter Ackerman collaborates with scholars based in United States, United Kingdom and France. Peter Ackerman's co-authors include Cyril Llamoso, Mindy Magee, Max Lataillade, Anne F. Luetkemeyer, Stephanie Noviello, Margaret Gartland, Jon Williams, Cheryl McDonald, Nancy Ratner and Dawn E. Quelle and has published in prestigious journals such as New England Journal of Medicine, SHILAP Revista de lepidopterología and Gastroenterology.

In The Last Decade

Peter Ackerman

29 papers receiving 514 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Peter Ackerman United States 11 232 176 165 142 125 30 523
Paul Cernohous United States 9 217 0.9× 179 1.0× 23 0.1× 26 0.2× 43 0.3× 17 457
Jay Lalezari United States 9 362 1.6× 191 1.1× 398 2.4× 432 3.0× 8 0.1× 11 801
Jill Lietzau United States 7 259 1.1× 180 1.0× 154 0.9× 12 0.1× 51 0.4× 11 672
Hélène Sauvageon France 10 179 0.8× 35 0.2× 122 0.7× 4 0.0× 93 0.7× 19 534
Juli Teague United States 6 110 0.5× 184 1.0× 154 0.9× 4 0.0× 13 0.1× 6 473
Steven G. Roberts United States 9 42 0.2× 86 0.5× 43 0.3× 20 0.1× 5 0.0× 12 566
Ana Serra‐Caetano Portugal 10 26 0.1× 32 0.2× 56 0.3× 8 0.1× 45 0.4× 13 478
Johannes Mejer Denmark 10 46 0.2× 29 0.2× 82 0.5× 11 0.1× 25 0.2× 29 397
Ernestina Tetteh United States 6 70 0.3× 41 0.2× 38 0.2× 8 0.1× 8 0.1× 6 343
J Maral France 10 51 0.2× 105 0.6× 58 0.4× 12 0.1× 5 0.0× 29 344

Countries citing papers authored by Peter Ackerman

Since Specialization
Citations

This map shows the geographic impact of Peter Ackerman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peter Ackerman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peter Ackerman more than expected).

Fields of papers citing papers by Peter Ackerman

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Peter Ackerman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peter Ackerman. The network helps show where Peter Ackerman may publish in the future.

Co-authorship network of co-authors of Peter Ackerman

This figure shows the co-authorship network connecting the top 25 collaborators of Peter Ackerman. A scholar is included among the top collaborators of Peter Ackerman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Peter Ackerman. Peter Ackerman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
3.
Ackerman, Peter, et al.. (2022). Interprofessional In Situ Simulation to Identify Latent Safety Threats for Quality Improvement: A Single-Center Protocol Report. Journal of Emergency Nursing. 49(1). 50–56. 3 indexed citations
4.
Krystal, Mark, Daren Austin, Max Lataillade, et al.. (2022). A Phase 1 randomized study of GSK3732394, an investigational long-acting biologic treatment regimen for HIV-1 infection. Antiviral Therapy. 27(5). 3867489135–3867489135. 1 indexed citations
5.
6.
Anderson, Sarah‐Jane, Miranda Murray, David Cella, et al.. (2021). Patient-Reported Outcomes in the Phase III BRIGHTE Trial of the HIV-1 Attachment Inhibitor Prodrug Fostemsavir in Heavily Treatment-Experienced Individuals. Patient. 15(1). 131–143. 2 indexed citations
7.
Wit, Stéphane De, et al.. (2021). 834. Characterization of Heavily Treatment Experienced HIV-1 Infected Clinical Trial Participants Infected with SARS-CoV-2 COVID 19: Fostemsavir BRIGHTE Phase 3 Clinical Trial. Open Forum Infectious Diseases. 8(Supplement_1). S509–S509. 1 indexed citations
8.
Lataillade, Max, Peter Ackerman, Till Schoofs, Andrew Clark, & Michael D. Miller. (2021). Fostemsavir in Heavily Treatment-Experienced Individuals Living with HIV-1: Insights from the Phase 3 BRIGHTE Study. 3(2). 2 indexed citations
9.
Magee, Mindy, et al.. (2020). Effect of Renal and Hepatic Impairment on the Pharmacokinetics of Temsavir, the Active Moiety of Fostemsavir. The Journal of Clinical Pharmacology. 61(7). 939–953. 7 indexed citations
10.
Lagishetty, Chakradhar V., et al.. (2020). Effects of Temsavir, Active Moiety of Antiretroviral Agent Fostemsavir, on QT Interval: Results From a Phase I Study and an Exposure–Response Analysis. Clinical and Translational Science. 13(4). 769–776. 17 indexed citations
11.
12.
Proudfoot, Clare, Peter Ackerman, Cyril Llamoso, et al.. (2018). 547. Results of Patient-Reported Outcome Data From the Phase III BRIGHTE Study of Fostemsavir. Open Forum Infectious Diseases. 5(suppl_1). S203–S203. 1 indexed citations
13.
Magee, Mindy, et al.. (2017). Pharmacokinetics of Temsavir, the Active Moiety of the Prodrug Fostemsavir, in Subjects with Hepatic Impairment. Open Forum Infectious Diseases. 4(suppl_1). S430–S430. 8 indexed citations
14.
Luetkemeyer, Anne F., Cheryl McDonald, Moti Ramgopal, et al.. (2016). 12 Weeks of Daclatasvir in Combination With Sofosbuvir for HIV-HCV Coinfection (ALLY-2 Study): Efficacy and Safety by HIV Combination Antiretroviral Regimens. Clinical Infectious Diseases. 62(12). 1489–1496. 45 indexed citations
15.
Swallow, Elyse, Jinlin Song, Yong Yuan, et al.. (2016). Daclatasvir and Sofosbuvir Versus Sofosbuvir and Ribavirin in Patients with Chronic Hepatitis C Coinfected with HIV: A Matching-adjusted Indirect Comparison. Clinical Therapeutics. 38(2). 404–412. 10 indexed citations
16.
Luetkemeyer, Annie, Cheryl McDonald, Moti Ramgopal, et al.. (2015). 12 Weeks of Daclatasvir in Combination With Sofosbuvir for HIV/HCV Coinfection (ALLY-2 Study): Efficacy and Safety by HIV Combination Antiretroviral Regimens. Open Forum Infectious Diseases. 2(suppl_1). 1 indexed citations
17.
Jonas, Maureen M., Mei‐Hwei Chang, Étienne Sokal, et al.. (2015). Randomized, controlled trial of entecavir versus placebo in children with hepatitis B envelope antigen–positive chronic hepatitis B. Hepatology. 63(2). 377–387. 51 indexed citations
18.
Miller, Shyra J., Fatima Rangwala, Jon Williams, et al.. (2006). Large-Scale Molecular Comparison of Human Schwann Cells to Malignant Peripheral Nerve Sheath Tumor Cell Lines and Tissues. Cancer Research. 66(5). 2584–2591. 158 indexed citations
19.
Ackerman, Peter, et al.. (2000). Nonviolent Power in the Twentieth Century. PS Political Science & Politics. 33(2). 147–148. 1 indexed citations
20.
Ackerman, Peter. (1993). ‘The economic aspects of Pacific security’: A reply. The Adelphi Papers. 33(275). 31–35.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Paul Cernohous Breakdown of academic impact, for papers by Jay Lalezari Breakdown of academic impact, for papers by Jill Lietzau Breakdown of academic impact, for papers by Hélène Sauvageon Breakdown of academic impact, for papers by Juli Teague Breakdown of academic impact, for papers by Steven G. Roberts Breakdown of academic impact, for papers by Ana Serra‐Caetano Breakdown of academic impact, for papers by Johannes Mejer Breakdown of academic impact, for papers by Ernestina Tetteh Breakdown of academic impact, for papers by J Maral
Rankless by CCL
2026